ResMed Continues To Build Digital-Medicine Business With $225M Acquisition Of Propeller Health
Propeller Health bills itself as a digital respiratory therapeutics company, providing a mobile platform that communicates with sensors on patients' inhaler devices to help them manage chronic obstructive pulmonary disease and asthma. This the second major acquisition ResMed has announced in the last month.
You may also be interested in...
ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 23 - Nov. 29, includes five-year data from the CoreValve US Pivotal Trial, the longest-term follow-up data from a randomized trial of Medtronic's CoreValve TAVR system, show it remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves. Also, results of a 2,800-patient study sponsored by Propeller Health, shows use of rescue-inhaler increased significantly along with increases in daily fine particulate matter exposure.
ResMed, one of the dominant players in the sleep-disorder market, has signed a definitive deal to buy Minnesota-based MatrixCare to augment its expanding software-as-a-service business with MatrixCare's electronic health record platform for long-term care settings.